Royalty Pharma (RPRX) Aktienübersicht
Royalty Pharma plc ist als Käufer von Lizenzgebühren für biopharmazeutische Produkte und als Förderer von Innovationen in der biopharmazeutischen Industrie in den Vereinigten Staaten tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 2/6 |
RPRX Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Royalty Pharma plc Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$57.79 |
| 52-Wochen-Hoch | US$60.44 |
| 52-Wochen-Tief | US$34.08 |
| Beta | 0.43 |
| 1 Monat Veränderung | 2.41% |
| 3 Monate Veränderung | 8.53% |
| 1 Jahr Veränderung | 61.15% |
| 3 Jahre Veränderung | 93.93% |
| 5 Jahre Veränderung | 47.84% |
| Veränderung seit IPO | 29.87% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Aug 05
Royalty Pharma: At The Right P/E, I'm In (But Not Here)
Summary Royalty Pharma is a market-leading pharmaceutical royalty company with a unique capital allocation model and a 60% industry share. RPRX offers exposure to blockbuster drug revenues with diversified risk but faces concentration in Vertex and lumpy milestone payments. Despite strong fundamentals and 10%+ expected top line CAGR, the current valuation (11-12x P/E) does not provide sufficient upside. I assign a 'Hold' rating with a $49/share target, requiring a better entry point for a 15% annualized return. Read the full article on Seeking Alpha
Narrative-Update • Aug 04
RPRX: New Royalty Deal And Buybacks Will Test Earnings Resilience
Analysts have lifted their Royalty Pharma price target by about $10 to $58. This reflects updated views on its revenue growth outlook, profit margins and future P/E assumptions.Recent updates
Seeking Alpha • Aug 05
Royalty Pharma: At The Right P/E, I'm In (But Not Here)
Summary Royalty Pharma is a market-leading pharmaceutical royalty company with a unique capital allocation model and a 60% industry share. RPRX offers exposure to blockbuster drug revenues with diversified risk but faces concentration in Vertex and lumpy milestone payments. Despite strong fundamentals and 10%+ expected top line CAGR, the current valuation (11-12x P/E) does not provide sufficient upside. I assign a 'Hold' rating with a $49/share target, requiring a better entry point for a 15% annualized return. Read the full article on Seeking AlphaNarrative-Update • Aug 04
RPRX: New Royalty Deal And Buybacks Will Test Earnings Resilience
Analysts have lifted their Royalty Pharma price target by about $10 to $58. This reflects updated views on its revenue growth outlook, profit margins and future P/E assumptions.Narrative-Update • Jul 03
RPRX: Royalty Deals And Buybacks Will Test Rich Earnings Assumptions
Royalty Pharma's analyst price target has shifted modestly higher, with updated fair value estimates moving from $46.00 to about $47.90 as analysts factor in revised assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary on Royalty Pharma Recent Street research on Royalty Pharma points to a more cautious tone beneath the modestly higher fair value estimates.
Narrative-Update • Jun 19
RPRX: Royalty Deals And Buybacks Will Support Long Term Stock Upside
Analysts have raised their price target for Royalty Pharma stock to $66.00 from $60.61, citing updated views on fair value, discount rate, expected revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Royalty Pharma points to a cluster of higher price targets and supportive commentary around valuation, execution, and growth prospects.
Narrative-Update • Jun 03
RPRX: Royalty Deals And Buybacks Will Shape Balanced Future Returns
Analysts have lifted their average price target for Royalty Pharma to about $59, up from roughly $52, citing updated views on long term revenue potential, higher expected profitability, and a lower assumed future P/E multiple. These factors are reflected in recent target increases from firms like Morgan Stanley and UBS, as well as positive commentary around the $250m Zymeworks financing deal.Narrative-Update • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.Narrative-Update • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Narrative-Update • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.Narrative-Update • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Narrative-Update • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Narrative-Update • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Analyseartikel • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narrative-Update • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Analyseartikel • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narrative-Update • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Narrative-Update • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Narrative-Update • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Narrative-Update • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Narrative-Update • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Narrative-Update • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Narrative-Update • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaAktionärsrenditen
| RPRX | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.5% | 4.3% | 0.09% |
| 1Y | 61.2% | 58.8% | 19.0% |
Rendite im Vergleich zur Industrie: RPRX wie die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 58.8 erzielte.
Rendite vs. Markt: RPRX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19 erzielte.
Preisvolatilität
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: RPRX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: RPRXDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc ist als Käufer von Lizenzgebühren für Biopharmazeutika und als Geldgeber für Innovationen in der biopharmazeutischen Industrie in den Vereinigten Staaten tätig. Das Portfolio des Unternehmens umfasst Lizenzgebühren für etwa 35 vermarktete Therapien und 20 Produktkandidaten im Entwicklungsstadium, die sich auf verschiedene therapeutische Bereiche beziehen, wie seltene Krankheiten, Onkologie, Neurowissenschaften, Infektionskrankheiten, Hämatologie und Diabetes. Das Unternehmen unterhält eine Forschungs- und Entwicklungskooperation, um die Entwicklung von JNJ-4804, einem Prüfpräparat für Autoimmunkrankheiten, voranzutreiben.
Royalty Pharma plc's Grundlagenzusammenfassung
| RPRX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$33.33b |
| Gewinn(TTM) | US$811.99m |
| Umsatz(TTM) | US$2.54b |
31.7x
Kurs-Gewinn-Verhältnis 10.1x
Kurs-Umsatz-VerhältnisIst RPRX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| RPRX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$2.54b |
| Kosten der Einnahmen | US$105.97m |
| Bruttogewinn | US$2.43b |
| Sonstige Ausgaben | US$1.62b |
| Gewinn | US$811.99m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 1.82 |
| Bruttomarge | 95.82% |
| Nettogewinnspanne | 32.02% |
| Schulden/Eigenkapital-Verhältnis | 91.6% |
Wie hat sich RPRX auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
1.6%
Aktuelle Dividendenrendite49%
AusschüttungsquoteZahlt RPRX eine zuverlässige Dividende?
Siehe RPRX Dividendenhistorie und Benchmarks| Royalty Pharma Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Aug 14 2026 |
| Datum der Dividendenzahlung | Sep 10 2026 |
| Tage bis Ex-Dividende | 2 days |
| Tage bis zum Datum der Dividendenzahlung | 29 days |
Zahlt RPRX eine zuverlässige Dividende?
Siehe RPRX Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/11 00:49 |
| Aktienkurs zum Tagesende | 2026/08/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Royalty Pharma plc wird von 14 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |